Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer

[1] Citron ML(2003)Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741 J Clin Oncol 21 1431-1439

[2] Berry DA(2015)Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial Lancet 385 1863-1872

[3] Cirrincione C(2010)Dose-dense chemotherapy in nonmetastatic breastcancer: a systematic review and meta-analysis of randomizedcontrolled trials J Natl Cancer Inst 102 1845-1854

[4] Del Mastro L(2015)Adjuvant dose-dense chemotherapyin breast cancer: a systematic review and meta-analysisof randomized trials Breast Cancer Res Treat 151 251-259

[5] De Placido S(2011)2010 update of EORTC guidelines for the use of granulocyte-colony stimulatingfactor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders andsolid tumours Eur J Cancer 47 8-32

[6] Bruzzi P(2006)2006 update ofrecommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187-3205

[7] Bonilla L(2002)Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer Ann Oncol 13 903-909

[8] Ben-Aharon I(2013)Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF) BMC Cancer 13 11-8347

[9] Vidal L(2005)Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy J Clin Oncol 23 8340-2051

[10] Gafter-Gvili A(2015)Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer Support Care Cancer 23 2045-751

[1] Citron ML(2003)Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741 J Clin Oncol 21 1431-1439

[2] Berry DA(2015)Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial Lancet 385 1863-1872

[3] Cirrincione C(2010)Dose-dense chemotherapy in nonmetastatic breastcancer: a systematic review and meta-analysis of randomizedcontrolled trials J Natl Cancer Inst 102 1845-1854

[4] Del Mastro L(2015)Adjuvant dose-dense chemotherapyin breast cancer: a systematic review and meta-analysisof randomized trials Breast Cancer Res Treat 151 251-259

[5] De Placido S(2011)2010 update of EORTC guidelines for the use of granulocyte-colony stimulatingfactor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders andsolid tumours Eur J Cancer 47 8-32

[6] Bruzzi P(2006)2006 update ofrecommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187-3205

[7] Bonilla L(2002)Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer Ann Oncol 13 903-909

[8] Ben-Aharon I(2013)Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF) BMC Cancer 13 11-8347

[9] Vidal L(2005)Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy J Clin Oncol 23 8340-2051

[10] Gafter-Gvili A(2015)Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer Support Care Cancer 23 2045-751